Dose Insider / Outsourcing pharmacies / STAQ Pharma, Inc.

STAQ Pharma, Inc.FDA registration and inspection record

FDA list of November 17, 2026 · checked against fda.gov on November 20, 2026

STAQ Pharma, Inc. in Denver, Colorado is registered with FDA as a 503B outsourcing facility, first on February 5, 2019 and most recently on December 18, 2025. FDA last inspected it on September 8, 2026 and issued a Form 483.

Inspected 2026last FDA inspection September 8, 2026
Facilities registered, by first yearFDA list of November 17, 2026; this facility’s year in coral2019, this one620203202112022420239202415202514202614Facilities registered, byfirst yearFDA list of November 17, 2026; this facility’syear in coral2019, this one620203202112022420239202415202514202614

From FDA’s list of registered outsourcing facilities, November 17, 2026.

On this page

These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.

What does FDA’s record show, in brief?

FacilitySTAQ Pharma, Inc.
LocationDenver, Colorado
Type503B outsourcing facility
Registered sinceFebruary 5, 2019
Latest registrationDecember 18, 2025
Last FDA inspectionSeptember 8, 2026
Inspection dates—
Form 483Issued
FDA action after the inspectionOpen
Compounds sterile drugs from bulkYes
FDA warning letters on GLP-1 drugs0

Has this facility recalled any drugs?

FDA’s enforcement reports list 6 recalled products from this facility, from February 3, 2022 to October 9, 2025: 2 in Class I, 1 in Class II, 3 in Class III. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3

StartedClassProductReason
2025-10-09IIIKetamine HydrochlorideLabeling: Incorrect or Missing Lot and/or Exp Date
2025-10-09IIIHydromorphone HCL PFLabeling: Incorrect or Missing Lot and/or Exp Date
2025-10-09IIIFentaNYL Citrate PFLabeling: Incorrect or Missing Lot and/or Exp Date
2023-11-29IIROPivacaine HCl 0.2% PF in Sodium Chloride 1STAQ Pharma Inc. received consumer complaints related to leaking bags and other potential bag concerns. Upon investigati…
2022-02-03IHYDROmorphone HCl PF 10 mg/50 mL (0.2mg/mL) in NaClLabeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphin…
2022-02-03IMorphine Sulfate PF 25 mg/25mL (1 mg/mL) in NaClLabeling: Label Mix up; A limited number of syringes containing HYDROmorphone HCl PF were incorrectly labeled as Morphin…

Is the pharmacy behind my prescription on FDA’s list?

Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.

Pharmacy check100 facilities
Registered 503B—
With a Form 483—

Where are the registered outsourcing facilities?

4 of the 100 facilities on FDA’s list are in Colorado. The chart counts them by state; choose a view to see which ones FDA has inspected.

Facilities by stateFDA list, November 17, 2026
Show
Facilities—
Top state—

Which other facilities are in the same state?

What does it mean that a pharmacy is a 503B outsourcing facility?

An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1

A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.

Sources

  1. FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
  2. FDA. Registered outsourcing facilities: inspection status of STAQ Pharma, Inc.. fda.gov
  3. FDA. Drug recall enforcement reports for STAQ Pharma, Inc., read through openFDA on November 20, 2026. open.fda.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider